On December 14th , the Patent Trial and Appeal Board rendered its decision on Preliminary Motions in Interference No. 106,133 between Senior Party Sigma-Aldrich and Junior Party The.
Following a telephone conference held on August 16th between the Board and representatives of Junior Party the Broad Institute, Harvard University, and MIT (collectively, Broad) and.
The parties in Interference No. 106,133, namely Senior Party Sigma-Aldrich and Junior Party the Broad Institute, Harvard University, and MIT (collectively, "Broad"), filed their.
• U.S. Patent Application No.14/704,551 – claims 2 and 4-18
• U.S. Patent Application No.15/330,876 – claims 1, 16-21, and 30-40,
against only one pending application for Toolgen:
• U.S. Patent Application Publication No. US20150344912 (Application No. 14/685,510) - claims 66-68, 70-74, 83, 85-88, and 90-94.
None of the claims of any of the patents or applications of either party were designated as not corresponding to the Count.
The count of the interference is set forth in the alternative, either as claim 18 of the Broad s U.S. Patent No. 8,697,359 (dependent on claim 15), which taken together recites the following invention:
An engineered, programmable, non-naturally occurring Type II CRISPR-Cas system comprising a Cas9 protein and at least one guide RNA that targets and hybridizes to a target sequence of a DNA molecule in a eukaryotic cell, wherein the DNA molecule encodes and the eukaryotic cell expresses at least one gene product and the Cas9 protein cleaves the